Volume 52, Issue 4, Pages (October 2007)

Slides:

Advertisements

Similar presentations

The PSA Era is not Over for Prostate Cancer

Advertisements

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Testosterone Therapy in Men With Prostate Cancer

Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer Marisa Warmuth,

Volume 72, Issue 5, Pages (November 2017)

Combination of Alfuzosin and Sildenafil is Superior to Monotherapy in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction Steven A. Kaplan,

Volume 64, Issue 4, Pages (October 2013)

Volume 71, Issue 4, Pages (April 2017)

Volume 66, Issue 6, Pages (December 2014)

Let the Games Begin (with EAU Approval)

Volume 68, Issue 1, Pages (July 2015)

Prostate Cancer Epidemic in Sight?

Volume 64, Issue 4, Pages (October 2013)

Volume 45, Issue 4, Pages (April 2004)

John P. Mulhall, Francesco Montorsi European Urology

Daily Administration of Phosphodiesterase Type 5 Inhibitors for Urological and Nonurological Indications Anthony J. Bella, Ling X. DeYoung, Mussa al-Numi,

Volume 56, Issue 1, Pages (July 2009)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Measuring the Urologic Iceberg: Design and Implementation of the Boston Area Community Health (BACH) Survey John B. McKinlay, Carol L. Link European.

Volume 51, Issue 1, Pages (January 2007)

Volume 54, Issue 4, Pages (October 2008)

A Systematic Review of Graft Augmentation Urethroplasty Techniques for the Treatment of Anterior Urethral Strictures Altaf Mangera, Jacob M. Patterson,

Volume 62, Issue 3, Pages (September 2012)

Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka

Volume 70, Issue 3, Pages (September 2016)

Long-Term Management of Overactive Bladder with Antimuscarinic Agents

Prostate Cancer Detection: A View of the Future

Low-risk Prostate Cancer: Identification, Management, and Outcomes

Volume 68, Issue 1, Pages (July 2015)

Volume 64, Issue 4, Pages (October 2013)

Volume 60, Issue 1, Pages (July 2011)

Volume 60, Issue 4, Pages (October 2011)

Volume 72, Issue 3, Pages (September 2017)

International Society of Urological Pathology Grading and Other Prognostic Factors for Renal Neoplasia Brett Delahunt, John R. Srigley, Lars Egevad,

Volume 47, Issue 5, Pages (May 2005)

Volume 70, Issue 1, Pages (July 2016)

Prostate Cancer Epidemic in Sight?

James N. Armitage, Stuart O. Irving, Neil A. Burgess European Urology

The PSA Era is not Over for Prostate Cancer

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Use of the National Health and Nutrition Examination Survey to Calculate the Impact of Obesity and Diabetes on Cost and Prevalence of Urolithiasis in.

The Economic Costs of Overactive Bladder in Germany

Karl-Dietrich Sievert, Bastian Amend, Arnulf Stenzl European Urology

Volume 54, Issue 4, Pages (October 2008)

Volume 62, Issue 6, Pages (December 2012)

Volume 70, Issue 1, Pages (July 2016)

Volume 50, Issue 5, Pages (November 2006)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Volume 55, Issue 3, Pages (March 2009)

Philip Toozs-Hobson, Pallavi Latthe European Urology Supplements

Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH):

Comparison of the Cardiovascular Effects of Tamsulosin Oral Controlled Absorption System (OCAS®) and Alfuzosin Prolonged Release (XL) Martin C. Michel,

Testicular Cancer Variations in Time and Space in Europe

Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH):

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Volume 72, Issue 5, Pages (November 2017)

European Urology is “Your” Journal

The Start-Up of the Platinum Journal: A Fascinating Challenge

Volume 75, Issue 1, Pages (January 2019)

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

Volume 4, Issue 5, Pages 2-3 (October 2006)

Economic Burden of Bladder Cancer Across the European Union

Statin use and clinical outcomes among pneumonia patients

Testim® Gel: Review of Clinical Data

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

Comparison of the Cardiovascular Effects of Tamsulosin Oral Controlled Absorption System (OCAS®) and Alfuzosin Prolonged Release (XL) Martin C. Michel,

Volume 54, Issue 1, Pages (July 2008)

Volume 51, Issue 5, Pages (May 2007)

Presentation transcript:

Volume 52, Issue 4, Pages 1195-1203 (October 2007) Treatment Outcomes in the STAR Study: A Subanalysis of Solifenacin 5 mg and Tolterodine ER 4 mg Christopher R. Chapple, Aino Fianu-Jonsson, Mark Indig, Vik Khullar, José Rosa, Roberto M. Scarpa, Arun Mistry, D. Mark Wright, John Bolodeoku European Urology Volume 52, Issue 4, Pages 1195-1203 (October 2007) DOI: 10.1016/j.eururo.2007.05.027 Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 1 Comparison of OAB improvements (and pad use) after 4 weeks active treatment (Randomised Treatment groups). Sol=solifenacin; tol=Tolterodine ER. European Urology 2007 52, 1195-1203DOI: (10.1016/j.eururo.2007.05.027) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 2 Comparison of OAB improvements (and pad use) at endpoint for NDI subgroups (treatment subgroups not requesting a dose increase). Endpoint=12 weeks or last clinic visit; NDI=No Does Increase. European Urology 2007 52, 1195-1203DOI: (10.1016/j.eururo.2007.05.027) Copyright © 2007 European Association of Urology Terms and Conditions